Aurobindo Pharma today said it has received final approval from the US health regulator to manufacture the generic version of Reckitt Benckiser's Mucinex DM cough relief tablets. The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets, 600/30 mg and 1200/60mg, Aurobindo Pharma said in a BSE filing. The tablets help loosen mucus and phlegm, and thin out bronchial secretions, making cough more productive, it added. The product will be launched in the first quarter of 2017-18, it said. Citing IRI data, Aurobindo Pharma said the tablets had an estimated market size of USD 235 million for the 12-months ended December 2016.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)